FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2036601083> ?p ?o ?g. }

• W2036601083 endingPage "318" @default.
• W2036601083 startingPage "309" @default.
• W2036601083 abstract "Optimal sequencing of cabazitaxel (C) and abiraterone acetate (A) after docetaxel (D) for metastatic castration-resistant prostate cancer (mCRPC) is unclear. We assessed treatment patterns and outcomes in patients with mCRPC receiving different sequences of A or C, or both, after administration of D.Retrospective analysis was conducted of US Oncology Network iKnowMed (iKM) electronic health record (EHR) data to assess patients with mCRPC who received treatment with D and were subsequently treated with C or A, or both, between April 2011 and May 2012. Patients received 2 or 3 drugs: DA, DC, DAC, or DCA. Overall survival (OS) and time to treatment failure (TTF) were analyzed by the Kaplan-Meier method from the start to the end of second-line therapy after administration of D (TTF1) and to the end of combined second- and third-line therapy (TTF2) for 3-drug sequences. Multivariable Cox proportional hazard models evaluated the impact of baseline clinical prognostic factors and treatment sequence on OS and TTF.Of 350 patients who were treated with D and subsequent therapies, 183 (52.3%) received DA, 54 (15.4%) received DC, 77 (22.0%) received DCA, and 36 (10.3%) received DAC. In a multivariable analysis, adjusted comparisons suggested that 3-drug sequences were associated with improved OS versus 2-drug sequences (hazard ratio [HR], 0.21; 95% confidence interval [CI], 0.092-0.476; P = .0002). There were no statistically significant differences in OS and TTF for DC versus DA, and OS was significantly greater for DCA versus DAC (HR, 0.13; 95% CI, 0.022-0.733; P = .0210). More cycles of C were administered in DCA than in DAC (median 6 vs. 4; t test P < .0001), whereas the duration of A treatment was similar.Administration of 3 agents in the DCA sequence was more optimal for treating mCRPC in this hypothesis-generating study." @default.
• W2036601083 created "2016-06-24" @default.
• W2036601083 creator A5006351491 @default.
• W2036601083 creator A5007453606 @default.
• W2036601083 creator A5007675629 @default.
• W2036601083 creator A5013681510 @default.
• W2036601083 creator A5015847653 @default.
• W2036601083 creator A5028687337 @default.
• W2036601083 creator A5050178081 @default.
• W2036601083 creator A5050901329 @default.
• W2036601083 creator A5052069729 @default.
• W2036601083 date "2015-08-01" @default.
• W2036601083 modified "2023-10-12" @default.
• W2036601083 title "Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices" @default.
• W2036601083 cites W1884893528 @default.
• W2036601083 cites W2036449946 @default.
• W2036601083 cites W2078559150 @default.
• W2036601083 cites W2080439368 @default.
• W2036601083 cites W2103959341 @default.
• W2036601083 cites W2110534364 @default.
• W2036601083 cites W2117783793 @default.
• W2036601083 cites W2120292596 @default.
• W2036601083 cites W2121023961 @default.
• W2036601083 cites W2123526148 @default.
• W2036601083 cites W2137467802 @default.
• W2036601083 cites W2141454098 @default.
• W2036601083 cites W2148643283 @default.
• W2036601083 cites W2165542862 @default.
• W2036601083 cites W2166918329 @default.
• W2036601083 cites W2170668585 @default.
• W2036601083 doi "https://doi.org/10.1016/j.clgc.2014.12.019" @default.
• W2036601083 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25743206" @default.
• W2036601083 hasPublicationYear "2015" @default.
• W2036601083 type Work @default.
• W2036601083 sameAs 2036601083 @default.
• W2036601083 citedByCount "40" @default.
• W2036601083 countsByYear W20366010832015 @default.
• W2036601083 countsByYear W20366010832016 @default.
• W2036601083 countsByYear W20366010832017 @default.
• W2036601083 countsByYear W20366010832018 @default.
• W2036601083 countsByYear W20366010832019 @default.
• W2036601083 countsByYear W20366010832020 @default.
• W2036601083 countsByYear W20366010832021 @default.
• W2036601083 countsByYear W20366010832022 @default.
• W2036601083 countsByYear W20366010832023 @default.
• W2036601083 crossrefType "journal-article" @default.
• W2036601083 hasAuthorship W2036601083A5006351491 @default.
• W2036601083 hasAuthorship W2036601083A5007453606 @default.
• W2036601083 hasAuthorship W2036601083A5007675629 @default.
• W2036601083 hasAuthorship W2036601083A5013681510 @default.
• W2036601083 hasAuthorship W2036601083A5015847653 @default.
• W2036601083 hasAuthorship W2036601083A5028687337 @default.
• W2036601083 hasAuthorship W2036601083A5050178081 @default.
• W2036601083 hasAuthorship W2036601083A5050901329 @default.
• W2036601083 hasAuthorship W2036601083A5052069729 @default.
• W2036601083 hasBestOaLocation W20366010831 @default.
• W2036601083 hasConcept C121608353 @default.
• W2036601083 hasConcept C126322002 @default.
• W2036601083 hasConcept C143998085 @default.
• W2036601083 hasConcept C207103383 @default.
• W2036601083 hasConcept C2775832370 @default.
• W2036601083 hasConcept C2776421732 @default.
• W2036601083 hasConcept C2777899217 @default.
• W2036601083 hasConcept C2778971682 @default.
• W2036601083 hasConcept C2780192828 @default.
• W2036601083 hasConcept C2781190966 @default.
• W2036601083 hasConcept C44249647 @default.
• W2036601083 hasConcept C50382708 @default.
• W2036601083 hasConcept C61367390 @default.
• W2036601083 hasConcept C71924100 @default.
• W2036601083 hasConceptScore W2036601083C121608353 @default.
• W2036601083 hasConceptScore W2036601083C126322002 @default.
• W2036601083 hasConceptScore W2036601083C143998085 @default.
• W2036601083 hasConceptScore W2036601083C207103383 @default.
• W2036601083 hasConceptScore W2036601083C2775832370 @default.
• W2036601083 hasConceptScore W2036601083C2776421732 @default.
• W2036601083 hasConceptScore W2036601083C2777899217 @default.
• W2036601083 hasConceptScore W2036601083C2778971682 @default.
• W2036601083 hasConceptScore W2036601083C2780192828 @default.
• W2036601083 hasConceptScore W2036601083C2781190966 @default.
• W2036601083 hasConceptScore W2036601083C44249647 @default.
• W2036601083 hasConceptScore W2036601083C50382708 @default.
• W2036601083 hasConceptScore W2036601083C61367390 @default.
• W2036601083 hasConceptScore W2036601083C71924100 @default.
• W2036601083 hasFunder F4320307781 @default.
• W2036601083 hasIssue "4" @default.
• W2036601083 hasLocation W20366010831 @default.
• W2036601083 hasLocation W20366010832 @default.
• W2036601083 hasOpenAccess W2036601083 @default.
• W2036601083 hasPrimaryLocation W20366010831 @default.
• W2036601083 hasRelatedWork W122177069 @default.
• W2036601083 hasRelatedWork W2010442426 @default.
• W2036601083 hasRelatedWork W2015876133 @default.
• W2036601083 hasRelatedWork W2568045406 @default.
• W2036601083 hasRelatedWork W2589688070 @default.
• W2036601083 hasRelatedWork W2591232777 @default.
• W2036601083 hasRelatedWork W2599742789 @default.
• W2036601083 hasRelatedWork W2768013934 @default.

• next